The study of the spectrum of pharmacological activity of the new original NT-3 mimetic dipeptide GTS-302

BACKGROUND: The association of the pathogenesis of neurodegenerative diseases, depression, anxiety, and cognitive disorders with the deficit of neurotrophin-3 determines the prospect of creating drugs with a similar mechanism of action. Since the use of full-size neurotrophin-3 is limited by unsatisfactory pharmacokinetic properties, it is relevant to create low-molecular-weight mimetics of neurotrophin-3 that are active when administered systemically. A dimeric dipeptide mimetic of the 4th loop of neurotrophin-3, hexamethylenediamide bis(N--oxibutyryl-L-glutamyl-L-asparagine) GTS-302, which activates TrkC and TrkB receptors, has been developed at the V.V. Zakusov Research Institute of Pharmacology. AIM: The aim of this study was to investigate the spectrum of pharmacological activity of GTS-302. MATERIALS AND МETHODS: The pharmacological effects of GTS-302 were investigated following its intraperitoneal administration. The antidepressant-like activity of GTS-302 was studied in the forced swim test in mice after acute and 7-day administration. The anxiolytic and cognitive activity of the dipeptide were studied in the elevated plus maze test in mice and the novel object recognition test in rats after acute administration, respectively. The effect of GTS-302 on pain sensitivity was studied in the hot plate test in mice after acute administration. RESULTS: It was found that GTS-302 exhibits antidepressant-like activity after acute administration at doses of 0.5, 1.0, 5.0 and 10 mg/kg. After 7-day administration, the antidepressant-like activity of GTS-302 was more pronounced in terms of effect size and statistical significance. The dipeptide GTS-302 at doses of 1.0, 5.0 and 10.0 mg/kg showed anxiolytic and cognitive activity and did not affect pain sensitivity. CONCLUSIONS: The pharmacological spectrum of the low-molecular-weight mimetic of neurotrophin-3, dipeptide GTS-302, revealed upon systemic administration includes a number of neuropsychotropic effects characteristic of the full-sized neurotrophin. This allows us to consider GTS-302 as a potential neuropsychotropic drug.

[1]  A. V. Tarasiuk,et al.  The First Dipeptide Mimetic of Neurotrofin-3: Design and Pharmacological Properties , 2022, Doklady Biochemistry and Biophysics.

[2]  Hui Wang,et al.  Neurotrophin-3 Promotes the Neuronal Differentiation of BMSCs and Improves Cognitive Function in a Rat Model of Alzheimer's Disease , 2021, Frontiers in Cellular Neuroscience.

[3]  A. Teixeira,et al.  Is neurotrophin-3 (NT-3): a potential therapeutic target for depression and anxiety? , 2020, Expert opinion on therapeutic targets.

[4]  T. Gudasheva,et al.  Low‐molecular mimetics of nerve growth factor and brain‐derived neurotrophic factor: Design and pharmacological properties , 2020, Medicinal research reviews.

[5]  I. Naletova,et al.  Copper complexes of synthetic peptides mimicking neurotrophin-3 enhance neurite outgrowth and CREB phosphorylation. , 2019, Metallomics : integrated biometal science.

[6]  A. Araszkiewicz,et al.  Melatonin and neurotrophins NT-3, BDNF, NGF in patients with varying levels of depression severity , 2016, Pharmacological reports : PR.

[7]  Maria V. Sanchez-Vives,et al.  Infralimbic Neurotrophin-3 Infusion Rescues Fear Extinction Impairment in a Mouse Model of Pathological Fear , 2016, Neuropsychopharmacology.

[8]  A. Wysokiński Serum levels of brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) in depressed patients with schizophrenia , 2016, Nordic journal of psychiatry.

[9]  P. Povarnina,et al.  Dimeric dipeptide mimetics of the nerve growth factor Loop 4 and Loop 1 activate TRKA with different patterns of intracellular signal transduction , 2015, Journal of Biomedical Science.

[10]  M. Escobar,et al.  Plasticity and metaplasticity of adult rat hippocampal mossy fibers induced by neurotrophin‐3 , 2013, The European journal of neuroscience.

[11]  J. Zhang,et al.  Neuroprotection of neurotrophin-3 against focal cerebral ischemia/reperfusion injury is regulated by hypoxia-responsive element in rats , 2012, Neuroscience.

[12]  M. Antunes,et al.  The novel object recognition memory: neurobiology, test procedure, and its modifications , 2011, Cognitive Processing.

[13]  F. Kapczinski,et al.  Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes. , 2010, Journal of psychiatric research.

[14]  Yu-Chin Li,et al.  Bivalent peptidomimetic ligands of TrkC are biased agonists and selectively induce neuritogenesis or potentiate neurotrophin-3 trophic signals. , 2009, ACS chemical biology.

[15]  M. Gratacós,et al.  Allele variants in functional MicroRNA target sites of the neurotrophin‐3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders , 2009, Human mutation.

[16]  W. Pan,et al.  Peptides and Hormesis , 2008, Critical reviews in toxicology.

[17]  A. Walf,et al.  The use of the elevated plus maze as an assay of anxiety-related behavior in rodents , 2007, Nature Protocols.

[18]  R. Jaenisch,et al.  NT-3 facilitates hippocampal plasticity and learning and memory by regulating neurogenesis. , 2006, Learning & memory.

[19]  K. Burgess,et al.  New templates for syntheses of ring-fused, C(10) beta-turn peptidomimetics leading to the first reported small-molecule mimic of neurotrophin-3. , 2002, Journal of medicinal chemistry.

[20]  E. Huang,et al.  Expression of Trk receptors in the developing mouse trigeminal ganglion: in vivo evidence for NT-3 activation of TrkA and TrkB in addition to TrkC. , 1999, Development.

[21]  G. L. Curran,et al.  Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. , 1996, Brain research. Molecular brain research.

[22]  N. Seidah,et al.  Cellular processing of the neurotrophin precursors of NT3 and BDNF by the mammalian proprotein convertases , 1996, FEBS letters.

[23]  C. Altar,et al.  Brain-derived neurotrophic factor and neurotrophin-3 activate striatal dopamine and serotonin metabolism and related behaviors: interactions with amphetamine , 1994 .

[24]  J. Siuciak,et al.  Antinociceptive effect of brain-derived neurotrophic factor and neurotrophin-3 , 1994, Brain Research.

[25]  S. File,et al.  Validation of open : closed arm entries in an elevated plus-maze as a measure of anxiety in the rat , 1985, Journal of Neuroscience Methods.

[26]  S. Handley,et al.  Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of ‘fear’-motivated behaviour , 1984, Naunyn-Schmiedeberg's Archives of Pharmacology.

[27]  R. Porsolt,et al.  Behavioural despair in rats: a new model sensitive to antidepressant treatments. , 1978, European journal of pharmacology.

[28]  K. Montgomery,et al.  The relation between fear induced by novel stimulation and exploratory drive. , 1955 .

[29]  M. Gratacós,et al.  5′ UTR-region SNP in the NTRK3 gene is associated with panic disorder , 2002, Molecular Psychiatry.